Mesoblast Ltd ADR (MESO) Stock Price, Quote & News

Latest News on MESO

Apr 3, 2025, 6:58 PM EDT - 8 days ago

Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin' and Not Subject to U.S. Tariffs

Apr 2, 2025, 7:15 PM EDT - 9 days ago

Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure

Mar 30, 2025, 7:39 PM EDT - 12 days ago

First Three Children to Commence Treatment With Ryoncil®

Mar 26, 2025, 8:19 PM EDT - 16 days ago

Ryoncil® is Now Available for Purchase in the United States

Mar 13, 2025, 7:42 PM EDT - 4 weeks ago

Ryoncil® Product Information Now Available in All Four Major Drug Pricing Compendia in United States

Mar 12, 2025, 7:30 AM EDT - 4 weeks ago

Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall

Feb 28, 2025, 11:38 AM EST - 6 weeks ago

Mesoblast Limited (MESO) Q2 2025 Earnings Call Transcript

Feb 26, 2025, 5:30 PM EST - 6 weeks ago

Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter

Feb 25, 2025, 6:13 PM EST - 6 weeks ago

Mesoblast Financial Results and Corporate Update Webcast

Feb 23, 2025, 6:33 PM EST - 6 weeks ago

Dr. Gregory George MD PhD Joins Mesoblast Board

Feb 13, 2025, 6:37 PM EST - 2 months ago

Ryoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings

Jan 30, 2025, 7:11 PM EST - 2 months ago

Ryoncil® Commercial Launch Update and Product Pipeline

Jan 30, 2025, 6:20 PM EST - 2 months ago

Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024

Dec 19, 2024, 6:38 AM EST - 4 months ago

Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges

Dec 18, 2024, 7:08 PM EST - 4 months ago

Mesoblast's RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy

Dec 18, 2024, 4:58 PM EST - 4 months ago

US FDA approves Mesoblast's cell therapy for graft-versus-host disease

Dec 18, 2024, 7:30 AM EST - 4 months ago

Mesoblast to be Added to Nasdaq Biotechnology Index

Dec 12, 2024, 12:08 PM EST - 4 months ago

RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead

CAPR XBI

Dec 4, 2024, 6:32 PM EST - 4 months ago

FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease

Dec 2, 2024, 6:20 PM EST - 4 months ago

Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation

Oct 30, 2024, 7:11 PM EDT - 5 months ago

Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024

Sep 30, 2024, 4:24 PM EDT - 6 months ago

Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential

Sep 29, 2024, 8:55 PM EDT - 6 months ago

Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch

Aug 28, 2024, 9:04 PM EDT - 8 months ago

Mesoblast Limited (MESO) Q4 2024 Earnings Call Transcript

Aug 28, 2024, 7:27 PM EDT - 8 months ago

Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024

Jul 30, 2024, 9:13 PM EDT - 9 months ago

Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024

$FDA Accepts Mesoblast's Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)$

Jul 23, 2024, 7:53 AM EDT - 9 months ago

FDA Accepts Mesoblast's Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

Jul 21, 2024, 8:45 PM EDT - 9 months ago

Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain

$Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)$

Jul 8, 2024, 8:37 PM EDT - 9 months ago

Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

Jul 1, 2024, 1:55 AM EDT - 10 months ago

Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week

Jun 2, 2024, 8:23 PM EDT - 11 months ago

Mesoblast Corporate Presentation at Investor Conference

Apr 29, 2024, 9:05 PM EDT - 1 year ago

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024

$United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)$